Retatrutide vs tirzepatide vs semaglutide — comparison of mono, dual, and triple incretin receptor agonists

Retatrutide vs Tirzepatide vs Semaglutide: A Complete Pharmacology Comparison

Written by: Reta Labs Scientific Content Team

Scientific Review: Current peer-reviewed literature on peptide research.

Last Updated: February 2026

Retatrutide vs tirzepatide vs semaglutide is really a comparison of three generations of incretin receptor pharmacology: one receptor, two receptors, three. Each generation added a target the previous couldn't reach, and each addition changed the metabolic picture. This guide compares them on mechanism, molecular structure, pharmacokinetics, trial evidence, and — the distinction that matters most — regulatory status. Reta Labs manufactures retatrutide research peptide in Canada, supplied strictly for laboratory research use only.

One thing to establish up front, because it governs everything below: semaglutide and tirzepatide are approved medicines, prescribed by clinicians. Retatrutide is not. It is investigational, unapproved anywhere, and exists as a research compound. The comparison here is pharmacological — how the three molecules work — not a ranking of treatment options, and nothing below suggests retatrutide is an alternative to an approved medicine.

Table of Contents

The Three Generations at a Glance

Semaglutide Tirzepatide Retatrutide
Receptors GLP-1 GLP-1 + GIP GLP-1 + GIP + glucagon
Class Mono-agonist Dual agonist Triple agonist
Developer Novo Nordisk Eli Lilly Eli Lilly
Brands Ozempic, Wegovy Mounjaro, Zepbound None (code LY3437943)
Length 31 amino acids 39 amino acids 39 amino acids
Acylation C18 diacid C20 diacid C20 diacid (γGlu-2xOEG linker)
Half-life ~1 week ~5 days ~6 days
Status Approved Approved Investigational (Phase 3)

Semaglutide: The Mono-Agonist

Semaglutide is a GLP-1 receptor agonist — a 31-amino-acid analogue of native GLP-1, stabilised with an Aib substitution that blocks DPP-4 cleavage and a C18 fatty-diacid acylation that enables albumin binding. Novo Nordisk markets it as Ozempic (type 2 diabetes) and Wegovy (obesity).

Its mechanism is the foundation the whole class is built on: glucose-dependent insulin secretion from pancreatic β-cells, glucagon suppression from α-cells, slowed gastric emptying, and central appetite signalling through hypothalamic and brainstem GLP-1 receptors. Everything tirzepatide and retatrutide do, they do in addition to this.

Tirzepatide: The Dual Agonist

Tirzepatide adds the GIP receptor. It is a 39-amino-acid peptide built on a GIP-based backbone rather than a GLP-1 one, with Aib substitutions and a C20 fatty-diacid acylation. Eli Lilly markets it as Mounjaro (type 2 diabetes) and Zepbound (obesity).

The GIP addition was counterintuitive at the time. GIP acting alone promotes lipid storage in adipose tissue, which looked like the wrong direction entirely. Tirzepatide's development showed the opposite in combination: GIP receptor agonism alongside GLP-1 agonism produced greater effects than GLP-1 alone. The proposed explanations involve GIP-mediated insulin sensitisation, adipocyte-biology changes, and central GIP effects that appear to reinforce GLP-1's appetite signalling — the receptor distributions overlap only partially, which is thought to contribute.

Retatrutide: The Triple Agonist

Retatrutide adds the glucagon receptor to that pairing. It is a 39-amino-acid peptide on a glucagon-family backbone, with Aib substitutions and a C20 fatty diacid attached through a γGlu-2xOEG linker. It carries Eli Lilly's development code LY3437943 and has no brand name, because it has never been approved.

Glucagon is the counterintuitive addition this time — it raises blood glucose, which appears to work directly against the point. But it also drives energy expenditure, lipolysis, and hepatic fat mobilisation. The design bet was that balanced glucagon activity, offset by strong GLP-1 and GIP glucose-lowering, could capture those effects without the hyperglycemia. That balance is why it's called a balanced triple agonist. For the full mechanism, see How Retatrutide Works and What Is Retatrutide?.

Receptor Mechanism Compared

All three engage class B G-protein coupled receptors that signal through Gαs coupling, adenylyl cyclase activation, and cAMP elevation. The machinery is shared; what differs is which receptors, in which tissues.

What each receptor contributes

  • GLP-1R — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite signalling. Present in all three compounds.
  • GIPR — amplified insulin secretion, adipose-tissue effects, additional central satiety signalling, bone-metabolism effects. Present in tirzepatide and retatrutide.
  • GCGR — hepatic lipid mobilisation, adipose lipolysis, increased energy expenditure, and hepatic glucose output. Unique to retatrutide.

The pattern

Each generation recruits mechanisms the previous one couldn't. GLP-1 alone works primarily on intake and insulin. Adding GIP amplifies that. Adding glucagon brings expenditure and hepatic lipid handling into play — a different side of the energy-balance equation entirely. For a deeper treatment, see GLP-1 vs GIP vs Glucagon Agonism.

Molecular Structure Compared

The three share a design language despite different backbones. All use Aib (α-aminoisobutyric acid) substitutions to block DPP-4 cleavage, which would otherwise degrade them within minutes. All use fatty-diacid acylation to bind serum albumin, which prevents rapid renal clearance and creates a slow-release depot — semaglutide with a C18 diacid, tirzepatide and retatrutide with C20.

The differences are in the backbone and the tuning. Semaglutide is modelled on GLP-1, tirzepatide on GIP, retatrutide on glucagon — each chosen as the template that best supports the intended receptor profile. Retatrutide's additional complexity lies in balancing potency across three receptors at once rather than one or two, which required tuning the activity ratio precisely enough that glucagon's glucose-raising effect stays offset.

Trial Evidence — and Why Cross-Trial Numbers Mislead

This is where most comparisons go wrong, so it's worth being careful.

The reported figures

Semaglutide's STEP-1 trial reported roughly 15% mean weight reduction at 68 weeks (2.4 mg). Tirzepatide's SURMOUNT-1 reported about 20.9% at 72 weeks (15 mg). Retatrutide's Phase 2, published in the New England Journal of Medicine in 2023, reported approximately 24.2% at 48 weeks (12 mg), and the Phase 3 TRIUMPH-1 readout in 2026 reported near 28% at 80 weeks.

Why you can't simply line those up

Those four numbers come from four different trials with different durations (48, 68, 72, and 80 weeks), different populations, different comparators, and different statistical estimands. A longer trial has more time to accumulate effect. Cross-trial comparison is suggestive, not evidence — a point that applies to every "X vs Y" table on the internet, including the one above.

The one head-to-head

There is exactly one direct comparison among these three, and it doesn't involve retatrutide. SURMOUNT-5, published in NEJM, compared tirzepatide against semaglutide head-to-head over 72 weeks, reporting −20.2% versus −13.7% — the first rigorous direct evidence that dual agonism outperforms mono-agonism in the same population under the same protocol. No equivalent head-to-head trial of retatrutide against either drug has reported. Until one does, retatrutide's apparent advantage rests on cross-trial inference.

Regulatory Status: The Decisive Difference

Everything above is pharmacology. This is the part that determines what these compounds actually are in practice.

Semaglutide and tirzepatide have been through complete clinical development, regulatory review, and approval. They are medicines, available on prescription, with established safety profiles, labelled indications, and clinician oversight. Retatrutide has none of that. It has not been approved by Health Canada, the FDA, or any other regulator; its Phase 3 program is still reporting, with trial status visible on ClinicalTrials.gov.

The gap matters more than the trial numbers. A larger reported effect in an unapproved compound is not evidence of a better option — it's an unfinished evaluation. Approval is what establishes that a compound's benefits and risks have been characterised well enough for use in people, and retatrutide hasn't reached that bar. It is supplied as research material for laboratory investigation, and that is the only capacity in which it exists outside a clinical trial.

What This Means for Research

For a laboratory, the three-generation progression is precisely what makes them useful together. Comparative designs use semaglutide as the GLP-1-only reference and tirzepatide as the dual reference to isolate what each additional receptor contributes — the only way to attribute an observed effect to the glucagon arm specifically is to hold the incretin background constant and compare.

That makes retatrutide most valuable in designs asking integrated questions — energy expenditure, hepatic lipid handling, multi-receptor signalling — rather than mechanism-isolation questions, where a single-receptor tool is cleaner. For how retatrutide compares to non-incretin research compounds, see Retatrutide vs Other Research Peptides; for sourcing standards, the Retatrutide Buying Guide. Reta Labs supplies retatrutide and the surrounding metabolic research peptide cluster at ≥99% HPLC purity with MS-verified identity and batch-specific COAs, strictly for research use only.

Frequently Asked Questions

What is the difference between retatrutide, tirzepatide, and semaglutide?

The number of receptors each engages. Semaglutide activates the GLP-1 receptor only; tirzepatide activates GLP-1 and GIP; retatrutide activates GLP-1, GIP, and glucagon. Each addition recruits metabolic biology the previous generation couldn't reach — GIP amplifying insulin and satiety signalling, glucagon adding energy expenditure and hepatic lipid mobilisation. Semaglutide and tirzepatide are approved medicines; retatrutide is investigational research material.

Is retatrutide stronger than tirzepatide or semaglutide?

Reported trial figures trend upward across the three, but the comparison is not as clean as it looks. Those numbers come from separate trials of different lengths and populations, and cross-trial comparison is suggestive rather than conclusive. The only head-to-head among them is SURMOUNT-5, which compared tirzepatide with semaglutide (−20.2% vs −13.7% at 72 weeks). No head-to-head trial of retatrutide against either has reported.

Can retatrutide be used instead of Ozempic or Zepbound?

No. Semaglutide and tirzepatide are approved medicines prescribed and monitored by clinicians. Retatrutide is not approved by any regulator and is not a treatment option; it is supplied strictly as a research-use-only material for laboratory investigation. Anyone considering an approved metabolic medicine should speak with a licensed medical professional.

Why does retatrutide activate the glucagon receptor?

Glucagon-receptor agonism contributes energy expenditure, adipose lipolysis, and hepatic fat mobilisation — effects the incretin receptors don't produce. Its drawback is that glucagon raises blood glucose. Retatrutide's design balances the three receptor activities so that GLP-1 and GIP glucose-lowering offsets the glucagon-mediated elevation, which is why the ratio between them is the central engineering feature.

Do all three use the same long-acting strategy?

Broadly yes. All three use Aib substitutions to resist DPP-4 degradation and fatty-diacid acylation to bind serum albumin, which prevents rapid renal clearance and extends circulation. Semaglutide uses a C18 diacid; tirzepatide and retatrutide use C20. Their half-lives land in a similar range — roughly five to seven days — which is what supports once-weekly dosing in trials.

Which is used in research, and why?

All three appear in comparative research designs, precisely because they form a mono/dual/triple ladder. Holding the incretin background constant and varying the added receptor is how a design attributes an observed effect to a specific pathway. Retatrutide is the tool for integrated multi-receptor questions; single- and dual-agonist references are cleaner for mechanism isolation.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.

Back to blog